Tests OPA-15406 foam against a vehicle in adults with atopic dermatitis
Tests OPA-15406 foam against a vehicle in adults with atopic dermatitis, a skin condition.
Plain-language title generated from the registry record
Registry title: A Phase 3 Trial to Demonstrate the Superiority of 1% OPA-15406 Foam to the Vehicle in Adult Patients With Atopic Dermatitis
Key facts
- Where
- Tokyo, JapanSee the site
- Phase
- Phase 3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 15 and 70 years old?
Source: NCT07173478, who can take part
Where in Japan
- Mita Dermatology ClinicTokyo, JapanNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Otsuka Pharmaceutical Co., Ltd.
- Trial code
- NCT07173478
- Record updated
- 15 September 2025
- Original description
To investigate the superiority of 1% OPA-15406 foam to the vehicle in adult patients with atopic dermatitis (AD).Read full original descriptionShow less
A Multicenter, Randomized, Double-blind, Vehicle-controlled, Parallel-group Comparison Trial to Demonstrate the Superiority of 1% OPA-15406 Foam to the Vehicle in Adult Patients With Atopic Dermatitis (Phase 3 Trial)
To investigate the superiority of 1% OPA-15406 foam to the vehicle in adult patients with atopic dermatitis (AD).
Inclusion: Participants who have been diagnosed AD based on the Diagnostic Criteria for Atopic Dermatitis (Criteria of the Japanese Dermatological Association); Participants with a history of AD for at least 3 years; Participants who have an affected area covering from 5% to 40% of their body surface area (excluding the scalp) at the screening and baseline examinations; Participants with an IGA score of 2 or 3 at the screening and baseline examinations.
Exclusion: Participants who experienced an acute exacerbation of AD or contact dermatitis within 28 days prior to the baseline examination; Participants who have been treated with OPA-15406 ointment in the past.